Zhong Cai, Chen Shijian, Zhang Jian, Luo Shuguang, Ye Ziming, Liu Yayuan, Pang Linlin, Dong Zimei, Qin Chao
Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Front Neurol. 2023 Jan 9;13:1074228. doi: 10.3389/fneur.2022.1074228. eCollection 2022.
Intracranial angioplasty with a self-expandable stent (SES) is an important endovascular therapy for symptomatic intracranial arterial stenosis. We sought to update the evaluation of the perioperative safety and long-term outcomes of self-expandable stent for the treatment of symptomatic intracranial arterial stenosis.
We comprehensively searched the published literature from each database through Sept 16, 2022, for the PubMed, EMBASE, Web of Science, Cochrane, and Clinical Trials databases. The characteristics of the studies and patients, perioperative complications, and long-term outcomes were extracted. The pooled outcomes and 95% confidence intervals (CIs) were estimated by Stata Statistical Software 14.0.
A total of 4,632 patients from 58 studies were included. The pooled rate of perioperative stroke or death was 6.32% (95% CI 5.04-7.72%); ischemic stroke beyond 30 days through 1 year was 2.72% (95% CI 1.41-4.38%). Perioperative complications differed between the 2014-2022 and 2005-2013 subgroups, as did long-term outcomes between the off-label SES and Wingspan subgroups.
The perioperative complications of intracranial angioplasty with SES have been reduced, but the risk of perioperative stroke or death is still higher than that of aggressive medical therapy, and additional studies are needed to determine whether it has better long-term outcomes than aggressive medical therapy. Perioperative complications varied between the 2014-2022 and 2005-2013 subgroups, as did long-term outcomes between the off-label SES and Wingspan subgroups. Given the high level of heterogeneity observed between the included studies, these results should be interpreted with caution and additional studies are needed.
https://www.crd.york.ac.uk/prospero/, identifier: CRD42022316066.
使用自膨式支架(SES)进行颅内血管成形术是治疗症状性颅内动脉狭窄的一种重要血管内治疗方法。我们试图更新对自膨式支架治疗症状性颅内动脉狭窄的围手术期安全性和长期疗效的评估。
我们全面检索了截至2022年9月16日每个数据库(包括PubMed、EMBASE、Web of Science、Cochrane和临床试验数据库)中已发表的文献。提取了研究和患者的特征、围手术期并发症及长期疗效。使用Stata统计软件14.0估计合并疗效及95%置信区间(CI)。
共纳入58项研究中的4632例患者。围手术期卒中或死亡的合并发生率为6.32%(95%CI 5.04 - 7.72%);30天以上至1年的缺血性卒中发生率为2.72%(95%CI 1.41 - 4.38%)。2014 - 2022年亚组与2005 - 2013年亚组的围手术期并发症不同,非标签SES亚组与Wingspan亚组的长期疗效也不同。
使用SES进行颅内血管成形术的围手术期并发症有所减少,但围手术期卒中或死亡风险仍高于积极药物治疗,需要更多研究来确定其长期疗效是否优于积极药物治疗。2014 - 2022年亚组与2005 - 2013年亚组的围手术期并发症不同,非标签SES亚组与Wingspan亚组的长期疗效也不同。鉴于纳入研究间观察到的高度异质性,这些结果应谨慎解读,还需要更多研究。